| Popis: |
To explore the feasibility of RhCcEe blood group antigen mixed visual field identification in patients with regular blood transfusion, to follow up and evaluate the efficacy of matched transfusion and its clinical significance.RhCcEe genotyping for 142 patients with regular transfusion in our hospital was carried out by PCR-SSP method. According to the results of genotyping, 48 patients voluntarily selected the continuous transfusion of RhCcEe matched red blood cells, 46 patients received random blood transfusion (RhCcEe mismatched transfusion), 42 patients received partial RhCcEe matched transfusion (unable to provide fully matched RhCcEe donors each time), and 6 patients' blood transfusion data were lost. After 3-6 months of the RhCcEe matched transfusion, all patients were tested by RhCcEe microcolumn gel card and compared with the results before RhCcEe matched transfusion. The positive rates of alloantibodies, DAT and the percentage of red blood cell invalid transfusion were followed up and evaluated for the above-mentsioned 3 types of regular transfusion patients in the past 5 years.Out of the 48 patients who underwent conti-nuous RhCcEe matched transfusion, only 1 case showed stratification, the remaining 47 cases had clear gel card results without stratification, suggesting that PCR-SSP genotyping was feasible. In addition, another 42 patients who could not receive RhCcEe matched transfusion each time and 46 patients with random blood transfusion were found to have a mixed vision phenomenon again. but the results was still difficult to confirm the results. For the transfusion results in the past 5 years, follow-up analysis showed that there were 1 case alloantibody (anti-Jka) (1/48) , 1 case of DAT positive (1/48) and 2 cases of invalid transfusion (2/48) in the RhCcEe matched transfusion group; 7 cases of alloantibodies (3 anti-E, 1 anti-E+anti-c, 1 anti-C, 1 anti-M, 1 anti-Fya) (7/46), 6 case of DAT positive (6/46) and 9 case of invalid transfusion (9/46) in the random transfusion group; 6 cases of alloantibodies (1 anti-E, 1 anti-E+autoantibody, 1 anti-C, 1 anti-c, 1 anti-M and 1 other antibody) (6/42) and 7 case of DAT positive (7/42) and 8 case of invalid transfusion (8/42) in the partial RhCcEe matched transfusion group. The statistical analysis showed that the positive rate of alloantibodies and the invalid infusion rate of RBC in each group were significant differences between RhCcEe matched transfusion group and the random transfusion group as well as betwen Rhce fe matched transfusion group and the partial matched transfusion group（P＜0.05）, but there was no statistical difference between the random transfusion group and the partial matched transfusion group（P0.05）.PCR-SSP genotyping technique can be used to detect RhCcEe mixed vision in patients with regular blood transfusion. Continuous RhCcEe matched transfusion can effectively prevent the occurrence of alloimmunization, and improve the clinical transfusion efficacy and safety of the patients with regular blood transfusion, which has very important clinical significance.定期输血患者RhCcEe混合视野鉴定及配型输注效果分析.探讨定期输血患者RhCcEe血型抗原混合视野鉴定的可行性，跟踪评价其配型输注效果及其临床意义.采用PCR-SSP方法对我院142例定期输血患者进行RhCcEe基因分型；根据基因分型结果，其中48例患者自愿持续进行RhCcEe同型输血，46例按临床输血规范进行RhCcEe随机输血，42例进行部分RhCcEe同型输血，6例患者流失了输血资料；在RhCcEe配型输注3-6个月后对所有患者采用RhCcEe微柱凝胶卡复查，并与他们配型输血前结果比较，跟踪评价近5年3类定期输血患者输血后同种抗体发生率、直接抗人球蛋白试验（DAT）阳性率及红细胞无效输注率.在48例持续RhCcEe同型输血患者中仅1例出现分层现象，其余47例凝胶卡结果清晰，此结果提示PCR-SSP基因分型的可行性；另外42例部分同型输血患者及46例随机输血患者凝胶卡检测仍然出现混合视野，结果较难确认。跟踪分析近5年输血效果显示，RhCcEe同型输血组发生同种抗体1例（抗-Jka）（1/48），DAT阳性1例（1/48），输注无效2例（2/48）；随机输血组同种抗体7例（抗-E 3例、抗-E+抗-c 1例、抗-C 1例、抗M 1例、抗-Fya 1例）(7/46)，DAT阳性6例(6/46)，输注无效9例（9/46）；部分RhCcEe配型输血组同种抗体6例（抗-E1例、抗-E合并自身抗体1例、抗-C 1例、抗-c 1例、抗-M 1例、其它1例）(6/42)，DAT阳性7例（7/42），输注无效8例（8/42）；统计学分析各组同种抗体阳性率与红细胞无效输注率显示，配型输血组与随机输血组、部分配型输注组间均有统计学差异（P＜0.05），而随机输血组与部分配型输血组间无统计学差异（P0.05）.PCR-SSP基因分型技术可应用于定期输血患者RhCcEe血型混合视野检测，持续RhCcEe配型输血可有效预防同种免疫产生，并提升定期输血患者临床输血效果与输血安全性，显示出具有一定的临床意义. |
